A phase 1 clinical trial of HWK-007 in non-small cell lung cancer and platinum resistant ovarian cancer
Latest Information Update: 09 Apr 2025
At a glance
- Drugs HWK 007 (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- 09 Apr 2025 New trial record
- 18 Mar 2025 According to Aadi Bioscience media release, this phase-1 study is planned in non-small cell lung cancer and platinum resistant ovarian cancer, with potential to expand into novel indications (e.g. gastrointestinal, gynecological).